Faculty Information - Masao Nakata

Present specialized field

BooK

Journal

Presentation

（Last updated : 2023-08-08 14:05:49）

Masao Nakata
Department Kawasaki Medical School Kawasaki Medical School, Department of General Thoracic Surgery,

Position Professor

■ Present specialized field

Respiratory surgery

■ BooK

2004

Evaluation of ischmic limbs by measuring transcutaneous oxygen tension and skin perfusion pressure, Breakthrough in the Treatment for Critical Limb Ischemia in Japan

■ Journal

1.	2023/05/19	Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201
2.	2023/01/11	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
3.	2022/09/17	Efects of tumor‑infltrating CD8+ T cells, PD1/PD‑L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra‑pleural pneumonectomy
4.	2022/03/23	A case of pleuroperitoneal communication during long-term steroid therapy for dermatomyositis
5.	2021/11	Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
6.	2021/08/06	The biological Characteristics of Solid Components are Different between Part-Solid-Type and Solid-Type in Lung Adenocarcinoma
7.	2021/05/24	Pulmonary Resection of the Primary Tumor for Patients with Stage IV Non-Small-Cell Lung Cancer
8.	2021/05/06	Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
9.	2021/01/24	Tofacitinib overcomes an IFNγ‐induced decrease in NK cell‐mediated cytotoxicity via the regulation of immune‐related molecules in LC‐2/ad
10.	2020/09/01	Perioperative Therapy for Non-Small Cell Lung Cancer - Current Status and Future Perspective -
11.	2019/12/01	Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC.
12.	2019/11/26	Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer
13.	2019/11	Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial
14.	2019/08	Effect of platinum-based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death-1 ligand 1 and HLA class I in non-small cell lung cancer
15.	2019/05	Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer
16.	2018/10	Deciduoid type malignant pleural mesothelioma: a case report
17.	2018/09	Epithelial-mesenchymal transition-induced metastasis could be a bait for natural killer cells
18.	2018/08	Impact of COX2 Inhibitor for Regulation of PD-L1 Expressioin in Non-small Cell Lung Cancer
19.	2018/05	A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
20.	2017/10	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
21.	2017/08	Urinary levels of prostaglandin E2 are positively correlated with intratumoral infiltration of Foxp3+ regulatory T cells in non-small cell lung cancer.
22.	2017/07	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
23.	2017/04	Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.
24.	2016/12	Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings
25.	2016/06	Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.
26.	2016/05	Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
27.	2016/03	MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small-cell lung cancer
28.	2015/12	Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
29.	2015/10	Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
30.	2015/09	Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer
31.	2015/09	Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small cell lung cancer
32.	2015/08	Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
33.	2015/02	Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
34.	2015/01	Cyclooxygenase-2 genetic variants influence intratumoral infiltration of Foxp3-positive regulatory T cells in non-small cell lung cancer.
35.	2014/11	Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
36.	2014/05	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma.
37.	2014/04	A case report of intrapulmonary schwannoma.
38.	2014	Clinical significance of vascular endothelial growth factor and Delta-like ligand 4 in small pulmonary adenocarcinoma
39.	2013/12	Lung cancer with sarcoid reaction in the lymph nodes following chemoradiotherapy
40.	2013/11	Case of pleural metastasis of prostate cancer.
41.	2013/11	Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer
42.	2013/09	Unknown primary large cell neuroendocrine carcinoma (LCNEC) in the mediastinum.
43.	2013/07	Clinical significance of the tumor microenvironment in non-small cell lung cancer
44.	2013/07	Role of 2-[18F]Fluoro-2-deoxyglucose positron emission tomography in Preoperative Management of Solid-Type Small-Sized Lung Cancer
45.	2013/06	Mucoid impaction of the bronchi caused by Mycobacterium avium
46.	2013/02	Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy
47.	2013/01	Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis
48.	2013	CT, MRI, and 18F-FDG PET-CT findings of pulmonary benign metastasizing leiomyoma: A case report
49.	2013	Heterogeneity of EGFR mutation status between primary tumor and metastatic lymph nodes and sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer
50.	2012/12	Current status of Radiologic Diagnosis for Mediastinal Lymph Node Metastases of Non-Small-Cell Lung Cancer: Retrospective Study of pN2 Cases
51.	2012/12	Successful Two-Stage Surgical Treatment for Lung Cancer in a Patient with Contralateral Giant Emphysematous Bullae
52.	2012/09	Characteristics of Non-Small Cell Lung Cancer Located in the Right Middle Lobe According to a Retrospective Study of Recurrence and Prognosis
53.	2012/07	Membrane-bound Estrogen Receptor-alpha Expression and Epidermal Growth Factor Receptor Mutation are Associated with a Poor Prognosis in Lung Adenocarcinoma Patients
54.	2012/04	Serial 3-dimensional volumetric computed tomography evaluation of lung cancer growth rate in patients with chronic obstructive pulmonary disease findings.
55.	2012/02	Current status of postoperative follow-up for lung cancer in Japan: questionnaire survey by the Setouchi Lung Cancer Study Group -A0901
56.	2012/02	Maximal Standardized Uptake Value on FDG-PET Is Correlated With Cyclooxygenase-2 Expression in Patients With Lung Adenocarcinoma
57.	2012	Stereotactic body radiotherapy for lung tumors: Preliminary results from a single institution.
58.	2011/10	Interstitial lung disease after re-administration of gefitinib in a responder with no adverse effects during the first administration: a case report
59.	2011/04	Solitary pulmonary nodule due to Mycobacterium kansasii.
60.	2010/11	A case of simultaneous lung cancer and abdominal aortic aneurysm treated with a two-stage strategy
61.	2010/10	Induction Chemoradiation Therapy with Cisplatin plus Irinotecan Followed by Surgical Resection for Superior Sulcus Tumor
62.	2010/10	Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma
63.	2010/05	Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer
64.	2010/04	Pulmonary Apical Mass,the So-Called Pulmonary Apical Cap,in a 43-Year-Old Woman
65.	2009/05	Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity
66.	2009/01	Evaluation of video-assisted thoracoscopic surgery for pulmonary metastases: 11-years of experience
67.	2009	Evaluation of video-assisted thoracoscopic surgery for pulmonary metastases: 11-years of experience.
68.	2008/08	Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan.
69.	2008/07	Teratoma with malignant transformation in the anterior mediastinum.
70.	2008/06	Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: differentiation from multiple atypical adenomatous hyperplasia.
71.	2008/06	Recent results regarding the clinical impact of smoking history on postoperative complications in lung cancer patients
72.	2008	How Can We Detect Curable Early Lung Cancers?
73.	2008	Lung Cancer with Localized Ground-Glass Attenuation Represents Early-Stage Adenocarcinoma in Nonsmokers
74.	2008	Mucosa - associated lymphoid tissue lymphoma in the thymus of a patient with systemic lupus erythematosus
75.	2008	Pappillary Fibroelastoma Developing from the Left Ventricular Septum
76.	2007/10	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung
77.	2007/09	Comparison in prognosis after VATS lobectomy and open lobectomy for stage I lung cancer: retrospective analysis focused on a histological subgroup.
78.	2007/05	Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma.
79.	2007	Pure red cell aplasia and myasthenia gravis with recurrent thymoma.
80.	2006/12	Inflammatory pseudotumor of the lung: clinicopathological analysis in seven adult patients.
81.	2006/02	Traumatic rupture of a right aortic arch in a patient with an aberrant left subclavian artery
82.	2005/10	Coexistence of metastatic lung cancer and pulmonary tuberculosis diagnosed in the same cavity
83.	2005/09	Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition
84.	2005	Objective radiologic analysis of ground-grass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer
85.	2004/12	ヴェグナー肉芽腫症との識別を要した肺腺癌(Lung Adenocarcinoma Required the Differentiation from Wegener Granulomatosis)
86.	2004	Surgical Treatments for Primary Adenocarcioma of the Lung
Display 5 items
Display all(86)

■ Presentation

1.	2022/08/06	Serum NY-ESO-1 and XAGE1 antibodies predict and monitor clinical responses to immune checkpoint therapy for NSCLC （Poster notice，General）
2.	2022/04/15	Conversion or salvage surgery for patients with unresectable stage III non-small-cell lung cancer （Speech，Panelist at Symposium/Workshop (Applied)）
3.	2021/11/01	Analysis of long-term outcomes after surgical resection in patients with non-small-cell lung cancer （Speech，General）
4.	2019/09/28	JAK-STAT inhibitor overcomes interferon g-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells. （Poster notice，General）
5.	2019/04/20	Clinical effectiveness of perioperative multi-disciplinary team management for lung cancer surgery （Speech，Panelist at Symposium/Workshop (Applied)）
6.	2018/12/08	3D-complete VATS curative resection for NSCLC （Speech，General）
7.	2018/10/04	Analysis of intraoperative critical situations in thoracoscopic surgery for NSCLC （Poster notice，General）
8.	2018/09/25	Adjuvant chemotherapy is effective for completely resected stage IB non-small cell lung cancer （Poster notice，General）
9.	2018/07/19	PD-L1 expression correlates with Cox-2 expression but is not down-regulated by Cox-2 inhibitor in lung cancer （Speech，General）
10.	2018/04/07	Local treatment for patients with oligometastatic non-small-cell lung cancer （Speech，General）
11.	2017/10/17	Prognostic Value of Cox-2 Expression Differs Depending on Tummor CD8+ T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma. （Poster notice，General）
12.	2017/10/17	Relationship between PD-L1 expression and EGFR/HER2 signaling in non-small-cell lung cancer （Poster notice，General）
13.	2017/09/28	Induction Therapy followed by Surgery for Borderline Resectable cN2 NSCLC （Poster notice，General）
14.	2017/09/11	Survival of non-small cell lung cancer patients predicted from expression of PD-L1, HLA class I and MICA/B on tumor cells （Poster notice，General）
15.	2016/12/07	Comparison of Clinicopathological and Immunohistochemical features in Lung Invasive Mucinous Adenocarcinomaaccording to Computed Tomography Findings. （Poster notice，General）
16.	2016/10/10	Repeated exposure to cisplatin enhances NK cell-mediated cytotoxicity via up-regulation of NKG2D ligands in non-small cell lung cancer cells （Poster notice，General）
17.	2016/06/03	A multi-center phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer （Poster notice，General）
18.	2015/12/19	Overexpression of NK cell-activating ligand MICA/B correlates with superior outcomes and might be a therapeutic target for chemo-immunotherapy in non-small-cell lung cancer. （Poster notice，General）
19.	2015/10/19	Evaluation of Novel Electronic Chest Drainage System after Anatomical Pulmonary Resection （Speech，General）
20.	2015/09/28	Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity by upregulating HER2 in malignant pleural mesothelioma cells （Poster notice，General）
21.	2015/09/09	Feasibility of Adjuvant Therapy with S-1 plus Carboplatin Followed by Maintenance Therapy with S-1 for Resected Non-Small-Cell Lung Cancer （Poster notice，General）
22.	2015/09/08	Investigation for the Optimum Resectable Pathological Size of Small Solitary Metastasis from Colorectal Cancers （Poster notice，General）
23.	2015/09/07	COX-2 Genetic Variants Influence Intratumoral Infiltration of Foxp-3-Positive Regulatory T Cells in Non-Small Cell Lung Cancer （Poster notice，General）
24.	2015/09/07	Randomized Feasibility Study of S-1 for Adjuvant Chemotherapy in Completely-Resected Stage IA Non-Small-Cell Lung Cancer (SLCG 0701) （Poster notice，General）
25.	2015/07/04	Clinical anatomy dissection by student doctors （Speech，General）
26.	2015/04/17	Challenge to Conversion Surgery for Locally Advanced Non-Small Cell Lung Cancer （Speech，General）
27.	2014/10/01	Current state of induction therapy followed by surgery for locally advanced NSCLC （Poster notice，General）
28.	2014/09/28	Cytotoxic anticancer drug enhances NK cell-mediated cytotoxicity via the DNA stress induced NKG2D ligands in non-small-cell lung cancer cells （Poster notice，General）
29.	2014/07/18	Cytotoxic drugs and EGFR tyrosine kinase inhibitor effect on NK cell cytotoxicity in non-small-cell lung cancer cells （Poster notice，General）
30.	2013/10/30	EGFR signaling effects on NK cell-mediated cytotoxicity via NKG2D ligands-NKG2D interaction in non-small cell lung cancer cells （Speech，General）
31.	2013/10/17	Perioperative management of anticoagulant and antiplatelet therapy for radical surgery of lung cancer （Speech，General）
32.	2013/09/28	Anticancer drugs effect on NK cell-mediated cytotoxicity via the regulation of NKG2D ligand expression in non-small cell lung cancer cells （Poster notice，General）
33.	2013/04/11	Post-recurrence survival and prognostic factors in completely resected non-small cell lung cancer （Poster notice，General）
34.	2012/09/30	HER signaling effects on the NK cell-mediated cytotoxicity via regulation of MHC class I-related chain A/ B in cancer cells （Poster notice，General）
35.	2011/10/12	Biomarker Expression of Primary Non-small Cell Lung Cancer and Metastatic Lympn Nodes （Speech，General）
36.	2011/07/05	Correlation of the standardized uptake value in FDG-PET with the biological marker in lung adenocarcinoma less than 3cm （Poster notice，General）
37.	2011/07/05	Significance of Delta-like ligand 4 (DLL4) on the angiogenesis in non-small cell lung cancer （Poster notice）
38.	2011/07/03	Phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvamt chemotherapy in resected NSCLC （Poster notice，General）
39.	2010/09/22	FDP-PET is superior to conventional CT in predicting histologic responses after induction therapy for locally advanced NSCLC （Speech，General）
40.	2010/09/20	Tumor-infiltrating Foxp3+ regulatory cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected NSCLC （Poster notice，General）
41.	2009/11/01	Tumor-Infiltrating Foxp3+ Regulaory T Cells Are Correlated with Cyclooxygenese-2 Expression and are associated with Recurrence in Resected Non-Small Cell Lung Cance （Poster notice，General）
42.	2009/08/03	Prognostic significance of eukaryotic initiation factor 4E and 4E binding protein 1 expression in patients with pathological stage 1 invasive lung adenocarcinoma （Poster notice，General）
43.	2009/08/03	Tumor Infiltrating Foxp3+ Regulatory T Cells Are Correlated with Cyclooxygenese-2 Expression and Associated with Recurrence in Resected NSCLC （Poster notice，General）
44.	2009/08/01	Significance of vascular endothelial growth factor polymorphisms on the angiogenesis in non-small cell lung cancer （Poster notice，General）
45.	2009/05	A multicenter, phase III study of CBDCA/PTX versus oral UFT as the adjuvant chemotherapy in resected NSCLC -Planned interim analysis- （Poster notice，General）
46.	2008/09/04	Two cases of necrotizing descending mediastinitis who underwent successful mediastinal drainage by a thoracoscopic approach （Poster notice）
47.	2007/10/13	Three cases of total aortic replacement for Marfan Syndrome （Speech，General）
48.	2007/09/02	Female adenocarcinoma express higher levels of estrogen receptors （Speech，General）
Display 5 items
Display all(48)